

TriNetX and Fujitsu launch JV to increase Japanese patients' access to life-changing medicines

13 February 2025 | News

Partnership taps real-world data to accelerate clinical trials, research, and drug development in Japan



TriNetX, a global leader in real-world data (RWD) and real-world evidence (RWE) solutions, has partnered with Fujitsu, a global ICT company and one of Japan's leading electronic health record (EHR) vendors, to form TriNetX Japan K.K.

This groundbreaking joint venture (JV) aims to quickly create an environment where anonymised EHR data from Japanese patients can be used to optimize clinical trials, advance healthcare research, and accelerate drug development timelines.

The initiative represents a significant step forward for integrating Japan into the global landscape of data-driven medicine and healthcare innovation. With its status as the third-largest pharmaceutical market worldwide, Japan offers unparalleled opportunities for clinical research and drug development. Additionally, Japan's rapidly aging population provides an ideal foundation for studying age-related conditions such as cancer, cardiovascular diseases, and neurodegenerative disorders.

The new entity will integrate the TriNetX LIVE Platform, TriNetX's global network of over 200 million patient records, with Fujitsu's cloud-based platform for the healthcare sector in Japan, offering a seamless connection between leading medical institutions and life sciences innovators. Through the integrated advanced analytics and data utilisation platforms, researchers and pharmaceutical companies will gain secure, efficient access to large-scale EHR datasets, revolutionising clinical trials and precision medicine initiatives.